Search research articles
Contact Us
Filters
Showing results (131-140 of 142) with videos related to
Page
of 15
Sort By:
European Journal of Clinical Pharmacology
|
October 29, 2015
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
Yoji Ishida, Kazunori Murai, Kohei Yamaguchi, et al.
International Journal of Hematology
|
July 9, 2017
Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan
Akio Saito, Atsushi Isoda, Masaru Kojima, et al.
Oncotarget
|
November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myeloma
Mariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Annals of Hematology
|
July 1, 2016
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era
Yutaka Tsukune, Makoto Sasaki, Takeshi Odajima, et al.
International Journal of Hematology
|
February 9, 2023
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL
Yasushi Onishi, Eijiro Furukawa, Mayumi Kamata, et al.
Molecular Cancer Research : MCR
|
January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
Mariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
Nutrients
|
November 27, 2021
Association between Milk Intake and Incident Stroke among Japanese Community Dwellers: The Iwate-KENCO Study
Kozo Tanno, Yuki Yonekura, Nagako Okuda, et al.
Journal of Clinical and Experimental Hematopathology : JCEH
|
July 31, 2024
Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma
Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, et al.
Blood
|
March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
Yasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
Annals of Hematology
|
September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 142) with videos related to
Sort By:
Page
of 15
European Journal of Clinical Pharmacology
|
October 29, 2015
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
Yoji Ishida, Kazunori Murai, Kohei Yamaguchi, et al.
International Journal of Hematology
|
July 9, 2017
Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan
Akio Saito, Atsushi Isoda, Masaru Kojima, et al.
Oncotarget
|
November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myeloma
Mariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Annals of Hematology
|
July 1, 2016
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era
Yutaka Tsukune, Makoto Sasaki, Takeshi Odajima, et al.
International Journal of Hematology
|
February 9, 2023
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL
Yasushi Onishi, Eijiro Furukawa, Mayumi Kamata, et al.
Molecular Cancer Research : MCR
|
January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
Mariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
Nutrients
|
November 27, 2021
Association between Milk Intake and Incident Stroke among Japanese Community Dwellers: The Iwate-KENCO Study
Kozo Tanno, Yuki Yonekura, Nagako Okuda, et al.
Journal of Clinical and Experimental Hematopathology : JCEH
|
July 31, 2024
Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma
Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, et al.
Blood
|
March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
Yasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
Annals of Hematology
|
September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
Page
of 15